• To be able to perform specialist assessment, treatment and counselling of non-small-cell lung cancer (NSCLC), including secondary prevention

  • Awareness of the existence of different biological and pathological subtypes of NSCLC that are used to individually personalise treatment

  • Awareness of the availability of different diagnostic procedures

  • Awareness of the existence of different prognostic factors

  • Recognition of the importance of the multimodality approach to treat patients with NSCLC

  • Appreciation of the principles of the multimodality approach in limited-stage disease

  • Awareness of the established and emerging biomarkers guiding therapy for NSCLC

  • Knowledge of the implications of the different biological and pathological subtypes of NSCLC for the selection of the appropriate treatment strategies

  • Familiarity with the different presentations of NSCLC and the tests available for work-up and staging

  • Familiarity with the indications for and limitations of the different diagnostic tools available for the identification of NSCLC (including fine needle aspiration (FNA), bronchoscopy)

  • Knowledge of the available treatments and the usual sequence in which they are given

  • Familiarity with the indications and value of surgery, radiation therapy, chemotherapy and immunotherapy in NSCLC, but also with their limitations (eg, criteria of operability)

  • Understanding of the role of chemotherapy, immunotherapy, targeted therapy and radiation therapy in the management of patients with advanced disease

  • Knowledge which complications arise from disease progression and which are treatment-associated

  • Understanding of the strengths of treatment personalisation opportunities and the importance of offering individualised targeted therapies on the basis of molecular findings, such as epidermal growth factor receptor (EGFR) mutations, echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) and ROS translocation and programmed death-ligand 1 (PD-L1) expression

  • Familiarity with supportive and palliative care strategies

  • Ability to identify patients at high risk for developing lung cancer who should undergo screening studies

  • Ability to perform a history and physical examination in NSCLC patients, including different subtypes, and to interpret imaging studies to appropriately stage the patients

  • Ability to contribute to discussions on general management strategies in order to understand the rationale for selecting and sequencing treatments in a multidisciplinary setting

  • Ability to prescribe various therapeutic agents considering their potential interactions with radiation therapy

  • Ability to effectively discuss data with patients regarding the impact of various treatments, and what would be recommended for them specifically

  • Ability to identify clinical scenarios where neoadjuvant and adjuvant therapy is appropriate

  • Ability to identify situations where surgery, radiation or multimodality therapy is preferred over systemic therapy alone

  • Ability to select therapy for advanced disease according to pathological subtype, molecular marker status and performance status

  • Ability to minimise and manage side effects from surgery, radiation or systemic therapies

  • Ability to guide a patient discussion about continuing anticancer therapy versus pursuing supportive care only